Opioid-associated amnestic syndrome: Description of the syndrome and validation of a proposed definition.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Oct 2020
Historique:
received: 27 05 2020
revised: 13 07 2020
accepted: 14 07 2020
pubmed: 3 8 2020
medline: 15 5 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

An opioid-associated amnestic syndrome (OAS) characterized by acute onset memory loss and bilateral hippocampal signal abnormalities on brain imaging in the setting of a history of opioid use, most notably fentanyl, has been reported. To date, however, there is no case definition to assist neurologists and other clinicians in identifying this syndrome. A multi-disciplinary collaboration of physicians, including neurologists, propose diagnostic criteria for OAS using cases that have been published in the medical literature or presented at conferences. Cases were classified as confirmed, probable, or possible based on brain imaging findings and history or analytical testing supporting opioid use. Published articles and presentations were identified by discussion with public health authorities and a systematic search of PubMed. Included were articles, abstracts or posters through November 2019 that presented case reports or case series of a new-onset amnestic syndrome associated with bilateral hippocampal injury on imaging and/or prior opioid or other substance use. The percentages of cases that would meet confirmed, probable, or possible criteria were calculated. Twenty-three publications from all sources met criteria for inclusion, accounting for 40 unique cases. Based on the case definition of OAS, 50% (20/40) were confirmed, 25% (10/40) were probable and 25% (10/40) were possible. The development of a validated, formal case definition for OAS can assist neurologists and other clinicians in evaluating patients with amnesia and a history of opioid use.

Identifiants

pubmed: 32739497
pii: S0022-510X(20)30385-3
doi: 10.1016/j.jns.2020.117048
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Fentanyl UF599785JZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117048

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Boyle reports participating in legal consultation.

Auteurs

Jed A Barash (JA)

Department of Medicine, Soldiers' Home, Chelsea, MA, USA. Electronic address: jed.barash@mass.gov.

James Whitledge (J)

Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

C James Watson (CJ)

Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Katherine Boyle (K)

Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Chun Lim (C)

Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Michael H Lev (MH)

Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.

Alfred DeMaria (A)

Massachusetts Department of Public Health, Jamaica, Plain, MA, USA.

Michael Ganetsky (M)

Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH